← Lymphatic Malformation Variant Atlas
c.1799T>A NM_004333.6 RAS-MAPK transversion, gain of function
| ISSVA subset | Allele fraction | Sources |
|---|---|---|
| LM | 0.1-3.6% (ddPCR; Zenner Table 1) | |
| GLA | 0.2-8% | |
| KLA | 0.2-2.2% | |
| CCLA | Li 2023: 0.91% (CLA060); Fox 2025: 2.2-2.6% (Patient 1) |
Bars show the reported allele-fraction range on a 0 to 50 percent axis.
Driver of the RAS-MAPK pathway. Repurposed drugs already used in the clinic for this pathway: trametinib and other MEK inhibitors.
Mentioned in 29,826 publications indexed by Europe PMC.